Rallybio Corp 8-K

What Happened

• Rallybio Corporation (RLYB) reported in an 8‑K filed May 4, 2026 that Candid Therapeutics, Inc. terminated the Agreement and Plan of Merger and Reorganization (the Merger Agreement). Candid terminated the Merger Agreement on May 3, 2026 and concurrently entered a Permitted Alternative Agreement with UCB S.A.
• As a result of that termination, Rallybio is entitled to a $50,000,000 Parent Termination Fee. On May 1, 2026 Rallybio, Candid and UCB executed a Waiver to the Merger Agreement that addresses timing of payment, mutual releases of claims, and certain waivers of Rallybio’s rights under the original agreements. Rallybio also intends to withdraw its Form S‑4 registration statement (initially filed March 17, 2026; amended April 24, 2026).

Key Details

• $50,000,000 Parent Termination Fee payable to Rallybio as specified in the Merger Agreement.
• Waiver dated May 1, 2026 among Rallybio, Candid and UCB (filed as Exhibit 2.1) permits payment of the termination fee and certain expense reimbursement on the first business day after termination.
• Under the Waiver, Rallybio agreed to waive certain rights related to Company notices and, subject to receiving the fee and expense reimbursement, release claims against Candid, UCB and their affiliates; Candid and UCB likewise released Rallybio’s parent and affiliates.
• The original Merger Agreement was entered March 1, 2026; Rallybio intends to withdraw its related S‑4 registration.

Why It Matters

• Cash impact: Rallybio is contractually entitled to receive $50M, which could affect near‑term liquidity and planning depending on timing of receipt.
• Strategic impact: The termination ends the planned merger/acquisition with Candid and the alternative transaction with UCB proceeded instead, so anticipated combined‑company synergies or business plans tied to the deal will not occur.
• Legal/contractual position: The Waiver includes mutual releases and Rallybio’s waiver of certain rights, which limits future claims related to the terminated merger; investors should note these settlements when assessing potential contingent claims or upside tied to the transaction.